Kleo Pharmaceuticals Presents Preclinical Data on KPMW135, a Novel CD3 x CD20 Bispecific Version of Rituximab, Showing Increased Anti-Tumor Activity Compared to Rituximab, at The 62nd Annual American Society of Hematology (ASH) Meeting

NEXT STORY
Affimed Announces Updated AFM13 Clinical Data Presentation at the American Society of Hematology Annual Meeting, Demonstrating Good Tolerability and a High Objective Response Rate in Patients with Recurrent/Refractory CD30-positive Lymphoma
PREV STORY
MannKind Expands Its Pipeline with the Acquisition of QrumPharma, Inc.
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Geron Reports Imetelstat Oral Presentation at European Hematology Association Congress

Updated Clinical Data from Original Part 1 of IMerge in Myelodysplastic Syndromes (MDS) PresentedMENLO ...

author_avatar
NASDAQ Market News

Landmark Study Published in American Journal of Obstetrics & Gynecology Validates New Blood Test as Objective, Predictive Tool for Preterm Birth Risk

SALT LAKE CITY, March 10, 2016 (GLOBE NEWSWIRE) -- Sera Prognostics, Inc., a women’s ...

author_avatar
NASDAQ Market News

Merus Announces Second Quarter 2017 Financial Results and Highlights Recent Progress

UTRECHT, The Netherlands, Sept. 19, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology ...

author_avatar
NASDAQ Market News